Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)-Reference-Cited by-同舟云学术

Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)

Published:2012-11-18 Issue:1 Volume:137 Page:93-107
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Kubo Makoto,Kanaya Noriko,Petrossian Karineh,Ye Jingjing,Warden Charles,Liu Zheng,Nishimura Reiki,Osako Tomofumi,Okido Masayuki,Shimada Kazuo,Takahashi Masato,Chu Peiguo,Yuan Yate-Ching,Chen Shiuan

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-012-2332-x.pdf

Reference46 articles.

1. Josefsson ML, Leinster SJ (2010) Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy. Breast (Edinb, Scotl) 19(2):76–83

2. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135–1141

3. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377(9762):321–331

4. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Lang I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thurlimann B (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12(12):1101–1108

5. Wong C, Chen S (2012) The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance. J Steroid Biochem Mol Biol 131(3–5):83–92

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Form-deprivation myopia promotes sclera M2-type macrophages polarization in mice;Biochemical and Biophysical Research Communications;2024-12

2. Obesity, dysbiosis and inflammation: interactions that modulate the efficacy of immunotherapy;Frontiers in Immunology;2024-08-26

3. Advances in targeting histone deacetylase for treatment of solid tumors;Journal of Hematology & Oncology;2024-05-31

4. Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers;Scientific Reports;2023-11-24

5. Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1;Nutrients;2023-03-28